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Abstract
Fibrotic disorders are commonplace, take many forms and can be life-threatening. No better example of this exists
than the progressive fibrosis that accompanies all chronic renal disease. Renal fibrosis is a direct consequence of
the kidney’s limited capacity to regenerate after injury. Renal scarring results in a progressive loss of renal function,
ultimately leading to end-stage renal failure and a requirement for dialysis or kidney transplantation.
Although it manifests itself histologically as an increase in extracellular matrix, we know that the histological
appearance can be caused by a de novo synthesis of matrix (primarily collagen), or a disproportionate loss of renal
parenchyma. In both cases the process depends on a resident mesenchymal cell, the so-called myofibroblast, and
is independent of disease etiology. Potentially we can ameliorate fibrosis, either indirectly by modifying the
environment the kidney functions in, or more directly by interfering with activation and function of myofibroblasts.
However, while renal fibrosis shares many features in common with the wound healing response in other organs,
we also recognise that the consequences can be highly kidney specific. This review highlights the similarities and
differences between this process in the kidney and other organs, and considers the therapeutic implications.
Introduction
Fibrosis involves an excess accumulation of extracellular
matrix (primarily composed of collagen) and usually
results in loss of function when normal tissue is replaced
with scar tissue [1]. No better example of this exists than
the progressive fibrosis that accompanies all chronic renal
disease. However, an overview of renal disease suggests
that complementary but different mechanisms are respon-
sible for fibrosis. Likewise, although there are obvious par-
allels between fibrosis in the kidney and elsewhere, there
are also a number of important differences, and kidney
specific consequences, that distinguish progressive renal
disease. The purpose of this review is to summarise the
mechanisms of renal fibrosis and its causes and conse-
quences. In doing so it will emphasise the similarities and
differences between the renal response and that of other
organs.
Discussion
Etiology of renal disease
Kidney disease consists of a diverse range of etiologies,
including immunological, mechanical, metabolic and toxic
insults amongst others. These variously affect the three
functional compartments of the kidney; the vasculature,
glomerulus and tubulointerstitium. It is these compart-
ments that are collectively responsible for the delivery of
blood, plasma filtration and modification of the glomerular
filtrate respectively. Regardless of etiology, all patients with
chronic kidney disease show a decline in renal function
with time [2]. The process is irreversible, inevitably leading
to end-stage renal failure, a condition that requires life-
long dialysis or renal transplantation. Histologically end-
stage kidney disease manifests itself as fibrotic lesions
affecting each compartment; glomerulosclerosis, vascular
sclerosis and tubulointerstitial fibrosis (Figure 1). Even
though matrix synthesis is of course part of the normal
repair process that occurs after injury, excessive synthesis
of extracellular matrix is itself destructive, further exacer-
bating injury in a vicious cycle. Correspondence: tim.hewitson@mh.org.au
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We perhaps most commonly associate scarring with an
excess synthesis of matrix, usually collagen. Keloids for
instance represent a quintessential example of scarring
which results from aberrant matrix synthesis. Neverthe-
less, although keloids are an extreme case, mechanistically
similar processes occur in deep organ fibrosis. There are
certainly renal parallels of this process, such as the focal
scarring that accompanies a localised tissue trauma.
What does however now seem clear, is that aberrant
matrix synthesis is only part of the process [3]. Temporal
studies in experimental renal infection indicate that aber-
rant collagen synthesis is often transient, peaking in the
first few days after infection. Histologically however, scar-
ring as defined by increasing matrix density, continues to
increase [4].
How can we account for this discrepancy? Although it
has long been known that end-stage kidneys are smaller
than their unscarred counterparts, it is the focal lesions
found in diseases such as reflux nephropathy that provide
us with a clue. The irregular surface of these kidneys indi-
cates underlying scar tissue, highlighting the fibro-contrac-
tive nature of renal scarring. Once again, there are
established non-renal examples of this process. Wound
contraction has long been recognised as an integral part of
skin wound healing, with the drawing together of wound
edges an important part of wound closure [5]. Direct renal
evidence comes from examining the histology in experi-
mental renal infection and scarring. Being a primary tubu-
lointerstitial model of injury, the glomeruli are largely
unaffected during fibrosis, the density of glomeruli there-
fore providing a measure of parenchymal collapse. In what
we term the “balloon” hypothesis [3], fibrosis is therefore
due not only to an increase in matrix synthesis but also to
the collapse of the renal parenchyma. Analogous to deflat-
ing a balloon, we are effectively measuring the same
amount of matrix in a smaller volume. Morphometric stu-
dies in this model show that the combined effect of an
acute increase in collagen expression and a later collapse
of the renal parenchyma account for the progressive
increase in scar tissue [4].
What is the cellular basis of this process?
Fibrosis in all three anatomical compartments is asso-
ciated with the activities of a mesenchyme derived cell.
The interstitial fibroblast, glomerular mesangial cell and
vascular smooth muscle cell are phenotypically similar,
with the fibroblast and mesangial cell acquiring features
of smooth muscle when activated [5-7].
In each compartment the resident mesenchymal cell is
not only the principal extracellular matrix producing cell,
but is also the force for contraction and reorganisation of
extracellular matrix, thereby increasing its density [5].
The renal interstitial fibroblast is typical of all three sce-
narios and has been the focus of our studies of tubuloin-
terstitial fibrosis. Recognised by its de novo synthesis of
asmooth muscle actin (aSMA), activated fibroblasts, so-
called myofibroblasts, are a feature of all forms of progres-
sive renal disease where their accumulation is strongly
associated with disease progression [5,7]. Myofibroblasts
are probably derived from multiple sources, including not
only resident fibroblasts, but also pericytes, blood borne
precursors and transition of adjacent epithelial cells and
endothelial cells, the relative importance of each being the
subject of much conjecture [8].
Regardless, myofibroblasts proliferate locally, synthesise
the extracellular matrix components that constitute inter-
stitial fibrosis and contract and reorganise matrix to
increase its density. Epigenetic modifications lead to per-
sistent activation of the protooncogene Ras, perpetual
fibroblast proliferation and fibrogenesis [9]. These changes
are stable modifications that can be inherited through
multiple cell divisions. In what is a vicious cycle, interstitial
fibrosis is probably a cause of mechanical injury and
through a reduction in vascularization, increases hypoxia
[10].
Pro-fibrotic influences
Interstitial fibroblast function and differentiation is regu-
lated by a plethora of factors, with a variety of molecules
shown to directly influence renal mesenchymal cells in
vitro [5]. Differentiation of myofibroblasts, proliferation
and collagen synthesis are stimulated by a variety of
cytokines and growth factors derived from adjacent sti-
mulated tubular epithelial cells, endothelial cells, leuko-
cytes or from fibroblast themselves. Other influences
include mechanical forces and extracellular matrix itself.
Figure 1 Histology of end-stage kidney disease consists of
tubulointerstitial fibrosis (middle), glomerulosclerosis (bottom left)
and vascular sclerosis (top right). Silver methenamine/Masson
trichrome stain. Scale bar = 50 μm.
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tors, with the most compelling evidence being for trans-
forming growth factor b1( T G F b1 )a n dp l a t e l e td e r i v e d
growth factor (PDGF). Where kidney injury is persistent
or repeated, increasing numbers of injured epithelial
cells stall between the G2 and M phases of the cell
cycle, which results in an ongoing production of TGFb1
[11]. It is also likely that fibroblasts are stimulated more
directly in some diseases because high glucose concen-
trations [12] and angiotensin II [13] stimulate in vitro
r e n a lc o r t i c a lf i b r o b l a s tp roliferation and collagen
production.
Likewise the contraction of renal parenchyma is under
cytokine control. Most of what we know about collagen
reorganisation comes from in vitro studies of collagen gel
contraction and reorganisation. In a process that is directly
proportional to the number of cells present, fibroblasts
embedded in solidified collagen progressively contract
matrix to reduce gel diameter and increase matrix density.
We know that this process is dependent upon b1 integrins
found on the surface of renal fibroblasts. Blocking these
receptors with specific antisera is sufficient to abrogate
fibroblasts binding to collagen I, and in doing so abrogate
gel contraction [14]. Again however, the process is com-
plex and is due both to contraction in the surrounding
matrix, in the same way as a sea anemone retracts its ten-
tacles, and traction or migration of fibroblasts through
surrounding matrix, akin to the movement of a spider
through its web, pulling on the filaments.
Endogenous anti-fibrotic factors
As our understanding of myofibroblast function has
increased, we have come to appreciate that the actions of
pro-fibrotic factors are counteracted by the activities of
endogenous reno-protective agents [15]. Theoretically at
least it is the balance of these opposing factors that deter-
mine progression [16]. Several have been characterised
including hepatocyte growth factor [17], bone morpho-
genic protein-7 [18] and the hormone relaxin [19,20].
A common pathway?
Clearly, as outlined above, renal fibrosis can result from
different mechanisms - both excess matrix synthesis and
contraction independently and collectively contribute. In
many respects this parallels fibrosis in other organs. Kid-
ney fibrosis, as elsewhere, is dependent upon the recruit-
ment of a myofibroblast-like cell. The process is both
fibro-proliferative, fibrogenic and fibro-contractive, and
is under the influence of both pro-fibrotic factors
released during injury, and endogenous reno-protective
factors.
H o w e v e r ,t h e r ea r ean u m b e ro fd i f f e r e n c e sb e t w e e n
t h ek i d n e ya n do t h e ro r g a n sw h i c hi m p a c to nt h ei n
vivo consequences of injury (Table 1).
Firstly, and perhaps most importantly, is the inherent
complexity of the kidney. The kidney consists of more
than 20 different cell types. Not only does this exacerbate
the in situ consequences of injury but it also affects the
ability of the kidney to regenerate after an insult. The
clinical reality is that the delicate structure of the glomer-
ulus is particularly prone to damage, with very limited, if
any, capacity to regenerate.
Much renal disease is associated with breakdown of the
glomerular filtration barrier, and passage of excess protein.
Proteinuria is toxic, excess downstream tubular reabsorp-
tion of protein results in tubular inflammation and fibro-
sis. Patients who develop progressive renal failure also
retain solutes normally excreted by the healthy kidney.
The circulating uraemic serum consists of a complex mix-
ture of more that 50 known or putative toxins [21]; includ-
ing small water bound solutes, middle molecules and
protein bound molecules [22]. The influence of these tox-
ins on renal cell function is well recognised [21], with
direct evidence to show that uraemia is a permissive factor
in the pathogenesis of fibrosis systemically [23].
While the kidney is well vascularised, the high oxygen
consumption of tubules [24] makes them highly suscepti-
ble to any reduction in interstitial oxygen supply or deliv-
ery. It has for instance long been known that the kidney
accounts for almost 25% of the body’s resting oxygen
consumption [25]. Oxygen deprivation is sensed through
a refined molecular system whose activation has been
shown to initiate renal fibrosis in animal models [10,26].
H y p o x i ai sa l s op r o b a b l yb oth a consequence and cause
of further progression [10].
Finally, but not least of all, is the role of arterial pres-
sure dependent factors. Activation of the renin-angio-
tensin-aldosterone system (RAAS) is pivotal to the
pathogenesis of much renal disease [27], and accounts
in part for the close relationship between renal disease
and cardiovascular complications. Effects on fibrosis
may be both indirect (hypertension and mechanical
injury) and direct (angiotensin II mediated fibrogenesis
and contraction).
Therapeutic implications
Organ specific differences have therapeutic implications.
Renal specific factors result in renal specific treatment
strategies. For instance control of blood pressure and
angiotensin II are the most proven ways of preventing
progression [28] and secondary fibrosis in the kidney
[29]. They however have limited application outside the
reno-cardio vascular system, where hypotension prevails.
Likewise protein restriction can ameliorate the toxic
effects of proteinuria [30]. The challenge is therefore to
find those generic anti-fibrotic strategies that have poten-
tial to ameliorate progressioni nm u l t i p l eo r g a n s ,t h a ti s ,
the overlap. Inhibition of the profibrotic factors, use of
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blasts are all promising targets.
Conclusion
In conclusion, many chronic diseases progress by fibrosis,
amelioration of which can play an important role in
patient management. Clinical nephrology in particular is
inexorably linked to the histology of the renal biopsy . As
w el e a r nm o r ea b o u tt h eh i s t o l o g ya n dm e c h a n i s m so f
fibrosis, studies in both the kidney and elsewhere will
continue to identify potential organ specific and generic
therapeutic targets.
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Table 1 Renal specific factors contributing to kidney fibrosis
Factor Cause
1 Complexity Kidney consists of ~20 different cell types
2 Poor capacity for regeneration Damaged glomeruli do not regenerate
Each nephron is anatomically distinct
3 Toxins Protein leakage and tubule uptake
Uraemic milieu (>50 putative or proven toxins)
Proteinuria
Uraemia
4 Hypoxia High tubule demand for oxygen
5 Arterial pressure dependent Pivotal role of renin-angiotensin-aldosterone system
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